TORL BioTherapeutics secures $158 million to advance its ADC oncology pipeline through Series B-2 financing

CAR-T Digest - August 2020

10 Apr 2024: TORL BioTherapeutics secures $158 million to advance its ADC oncology pipeline through Series B-2 financing

TORL BioTherapeutics secures $158 million in Series B-2 financing led by Deep Track Capital
Funding includes participation from prominent biotechnology investors such as RA Capital Management and Perceptive Advisors
TORL-1-23 focuses on treating Claudin 6 positive (CLDN 6+) solid tumors, with Phase 2 trial planned for platinum-resistant ovarian cancer
Other programs include TORL-2-307, TORL-3-600, and TORL-4-500, targeting various tumor types
TORL aims to deliver breakthrough therapies for patients with unmet medical needs in cancer